
Maurizio Guido

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/743517/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Drospirenone for the Treatment of Hirsute Women with Polycystic Ovary Syndrome: A Clinical, Endocrinological, Metabolic Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2817-2823.	1.8	143
2	Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Human Reproduction, 2003, 18, 1210-1218.	0.4	127
3	Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism: Clinical and Experimental, 1999, 48, 167-172.	1.5	109
4	Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma?. Human Reproduction, 2006, 21, 3108-3115.	0.4	78
5	Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion**Supported by: grant 88.00479.11 of Consiglio Nazionale delle Ricerche, Roma, Italy Fertility and Sterility, 1992, 58, 296-301.	0.5	55
6	Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertility and Sterility, 2010, 93, 2303-2310.	0.5	49
7	Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Human Reproduction, 2004, 19, 534-539.	0.4	45
8	Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study. Fertility and Sterility, 2008, 90, 1826-1833.	0.5	45
9	Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective. Human Reproduction, 2008, 23, 2127-2133.	0.4	40
10	Assessment of insulin resistance in lean women with polycystic ovary syndrome. Fertility and Sterility, 2014, 102, 250-256.e3.	0.5	38
11	Follicular loss in endoscopic surgery for ovarian endometriosis: quantitative and qualitative observations. Fertility and Sterility, 2011, 96, 374-378.	0.5	32
12	Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertility and Sterility, 2007, 88, 131-138.	0.5	30
13	Metformin <i>vs</i> myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clinical Endocrinology, 2017, 86, 725-730.	1.2	30
14	Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities. Current Pharmaceutical Design, 2006, 12, 1001-1012.	0.9	29
15	The link between metabolic features and TSH levels in polycystic ovary syndrome is modulated by the body weight: an euglycaemic–hyperinsulinaemic clamp study. European Journal of Endocrinology, 2016, 175, 433-441.	1.9	28
16	Alteration of ghrelin–neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism. Clinical Endocrinology, 2008, 69, 562-567.	1.2	26
17	Role of opioid tone in the pathophysiology of hyperinsulinemia and insulin resistance in polycystic ovarian disease. Metabolism: Clinical and Experimental, 1998, 47, 158-162.	1.5	24
18	Administration of exogenous ghrelin in obese patients with polycystic ovary syndrome: effects on plasma levels of growth hormone, glucose, and insulin. Fertility and Sterility, 2007, 88, 125-130.	0.5	22

Maurizio Guido

#	Article	IF	CITATIONS
19	Metformin treatment does not affect total leptin levels and free leptin index in obese patients with polycystic ovary syndrome. Fertility and Sterility, 2008, 89, 1273-1276.	0.5	21
20	The Metabolic Status Modulates the Effect of Metformin on the Antimullerian Hormone-Androgens-Insulin Interplay in Obese Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E821-E824.	1.8	19
21	Involvement of Ovarian Steroids in the Opioid-Mediated Reduction of Insulin Secretion in Hyperinsulinemic Patients with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1742-1745.	1.8	16
22	How to improve MRI accuracy in detecting deep infiltrating colorectal endometriosis: MRI findings vs. laparoscopy and histopathology. Radiologia Medica, 2014, 119, 291-297.	4.7	15
23	Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome. Fertility and Sterility, 1997, 67, 34-39.	0.5	14
24	The use of different size-hysteroscope in office hysteroscopy: our experience. Archives of Gynecology and Obstetrics, 2013, 288, 1355-1359.	0.8	12
25	How Metformin Acts in PCOS Pregnant Women: Insights into insulin secretion and peripheral action at each trimester of gestation. Diabetes Care, 2013, 36, 1477-1482.	4.3	12
26	Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib. Leukemia and Lymphoma, 2014, 55, 709-710.	0.6	12
27	Endocrinology: Differential androgen response to adrenocorticotrophin hormone stimulation and effect of opioid antagonist on insulin secretion in polycystic ovarian syndrome. Human Reproduction, 1994, 9, 2242-2246.	0.4	11
28	Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase. Fertility and Sterility, 2009, 91, 1857-1863.	0.5	11
29	Opioid Blockade Effect on Insulin β-Cells Secretory Patterns in Polycystic Ovary Syndrome. Hormone Research in Paediatrics, 1998, 49, 263-268.	0.8	10
30	Fertility Preservation Methods in Breast Cancer. Breast Care, 2012, 7, 197-202.	0.8	10
31	Comparison of absorbable and permanent sutures for laparoscopic sacrocervicopexy: A randomized controlled trial. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 347-352.	1.3	10
32	Hypothalamic-pituitary-adrenal axis sensitivity to opioids in women with polycystic ovary syndrome. Fertility and Sterility, 2000, 73, 712-717.	0.5	9
33	Effect of metformin on the growth hormone response to growth hormone–releasing hormone in obese women with polycystic ovary syndrome. Fertility and Sterility, 2005, 84, 1470-1476.	0.5	9
34	Involvement of Ovarian Steroids in the Opioid-Mediated Reduction of Insulin Secretion in Hyperinsulinemic Patients with Polycystic Ovary Syndrome. , 0, .		8
35	Influence of body mass on the hypothalamic-pituitary-adrenal–axis response to naloxone in patients with polycystic ovary syndrome. Fertility and Sterility, 1999, 71, 462-467.	0.5	7
36	Ethinylestradio-Chlormadinone Acetate Combination for the Treatment of Hirsutism and Hormonal Alterations of Normal-Weight Women With Polycystic Ovary Syndrome: Evaluation of the Metabolic Impact. Reproductive Sciences, 2010, 17, 767-775.	1.1	5

#	Article	IF	CITATIONS
37	Carbon dioxide in office diagnostic hysteroscopy: An open question. A multicenter randomized trial on 1982 procedures. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 235, 97-101.	0.5	4
38	Effect of the opioid blockade on the feeding-induced growth hormone response to growth hormone-releasing hormone in women with polycystic ovary syndrome. Fertility and Sterility, 2002, 78, 994-1000.	0.5	3
39	Effect of corticotropin-releasing factor on the pituitary-ovary axis in human luteal phase. Gynecological Endocrinology, 1995, 9, 271-276.	0.7	2
40	Effect of gonadotropin-releasing hormone agonist treatment on growth hormone responses in women with polycystic ovary syndrome. Fertility and Sterility, 2004, 82, 250-252.	0.5	0